A Phase 3 interventional study of Empagliflozin and Empagliflozin in Diabetes Mellitus, Type 1, sponsored by Boehringer Ingelheim. Completed at 131 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 2nd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 730 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 49 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 7 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing empagliflozin in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Use of, and be willing, based on the Investigator's judgement, to continue throughout the duration of the trial, either:
Additional inclusion criteria may apply
Exclusion criteria:
Additional exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin tablets once daily
Drug: Empagliflozin
Empagliflozin tablets once daily
Drug: Empagliflozin
Placebo tablets matching empagliflozin once daily
Drug: Placebo
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26
Change from baseline in glycated haemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
Time frame: Baseline to week 26
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )
Change from baseline in glycated haemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
Time frame: Baseline to week 26
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
This is a key secondary endpoint. Rate per patient-year of investigator-reported symptomatic hypoglycaemia adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycaemia AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycaemia events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate.
Time frame: Week 5 to Week 26, Week 1 to Week 26
Change From Baseline in Body Weight at Week 26
Change from baseline in body weight is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26
Change from baseline in the percentage of time spent in target glucose range of \>70 to ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L) as determined by continuous glucose monitoring (CGM) is presented in week 23 to 26. Least squares mean is actually an adjusted event rate.
Time frame: Week 23 to 26
Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26
Change from baseline in interstitial glucose variability based on the IQR as determined by CGM is presented for week 23 to 26. Least squares mean is actually an adjusted event rate.
Time frame: Week 23 to 26
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Change from baseline in TDID is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Change from baseline in SBP and DBP is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Randomised, double-blind, placebo-controlled, parallel group, 52-week trial comparing 2 oral once daily doses (10 mg and 25 mg) of empagliflozin with placebo in patients with type 1 diabetes mellitus (T1DM), each as adjunctive to optimised insulin therapy.
| Milestone | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Started | 243 | 243 | 244 |
| Completed | 211 | 223 | 230 |
| Not completed | 32 | 20 | 14 |
| Withdrew: Adverse event | 6 | 6 | 3 |
| Withdrew: Protocol violation | 10 | 3 | 1 |
| Withdrew: Lost to follow-up | 7 | 4 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 | 5 |
| Withdrew: Other than specified | 4 | 4 | 5 |
Change from baseline in glycated haemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
| Percentage (%) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 | 0.09 ± 0.04 | -0.44 ± 0.04 | -0.44 ± 0.04 |
Change from baseline in glycated haemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
| Percentage (%) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) ) | 0.09 ± 0.04 | -0.43 ± 0.04 | -0.42 ± 0.04 |
This is a key secondary endpoint. Rate per patient-year of investigator-reported symptomatic hypoglycaemia adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycaemia AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycaemia events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate.
| Event per patient year | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Week 5 to 26 | 8.92 (7.15 to 11.14) | 6.64 (5.32 to 8.28) | 6.48 (5.18 to 8.12) |
| Week 1 to 26 | 9.13 (7.36 to 11.34) | 7.07 (5.70 to 8.76) | 7.15 (5.75 to 8.88) |
Change from baseline in body weight is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
| Kilogram (kg) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | -0.10 ± 0.21 | -2.79 ± 0.20 | -3.37 ± 0.20 |
Change from baseline in the percentage of time spent in target glucose range of \>70 to ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L) as determined by continuous glucose monitoring (CGM) is presented in week 23 to 26. Least squares mean is actually an adjusted event rate.
| Percentage of time | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26 | -1.13 ± 0.72 | 10.73 ± 0.71 | 11.74 ± 0.70 |
Change from baseline in interstitial glucose variability based on the IQR as determined by CGM is presented for week 23 to 26. Least squares mean is actually an adjusted event rate.
| milligrams (mg)/ deciliter (dL) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26 | 1.62 ± 1.21 | -15.30 ± 1.18 | -17.41 ± 1.16 |
Change from baseline in TDID is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
| Unit/kilogram (U/kg) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26 | -0.010 ± 0.007 | -0.102 ± 0.007 | -0.100 ± 0.007 |
Change from baseline in SBP and DBP is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
| Millimeters of mercury (mmHg) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| SBP | -0.8 ± 0.7 | -2.9 ± 0.7 | -4.5 ± 0.7 |
| DBP | -0.3 ± 0.5 | -1.6 ± 0.5 | -2.6 ± 0.5 |
Collected over From the first dose of trial medication until 7 days after last in-take of trial medication, up to 422 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching Empagliflozin | 0/243 (0%) | 28/243 (11.5%) | 197/243 (81.1%) |
| Empagliflozin 10 mg | 0/243 (0%) | 43/243 (17.7%) | 197/243 (81.1%) |
| Empagliflozin 25 mg | 0/244 (0%) | 26/244 (10.7%) | 195/244 (79.9%) |
| Event | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 4/243 | 12/243 | 8/244 |
| HypoglycaemiaMetabolism and nutrition disorders | 6/243 | 9/243 | 3/244 |
| KetoacidosisMetabolism and nutrition disorders | 2/243 | 4/243 | 2/244 |
| FallInjury, poisoning and procedural complications | 0/243 | 2/243 | 0/244 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/243 | 1/243 | 1/244 |
| DeafnessEar and labyrinth disorders | 0/243 | 0/243 | 2/244 |
| PneumoniaInfections and infestations | 0/243 | 0/243 | 2/244 |
| Acute myocardial infarctionCardiac disorders | 1/243 | 0/243 | 0/244 |
| Cardiac failure congestiveCardiac disorders | 0/243 | 1/243 | 0/244 |
| Coronary artery stenosisCardiac disorders | 0/243 | 1/243 | 0/244 |
| Event | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 152/243 | 154/243 | 147/244 |
| NasopharyngitisInfections and infestations | 41/243 | 52/243 | 43/244 |
| Urinary tract infectionInfections and infestations | 29/243 | 37/243 | 20/244 |
| Upper respiratory tract infectionInfections and infestations | 25/243 | 15/243 | 27/244 |
| InfluenzaInfections and infestations | 11/243 | 20/243 | 12/244 |
| Blood ketone body increasedInvestigations | 10/243 | 18/243 | 20/244 |
| VomitingGastrointestinal disorders | 12/243 | 19/243 | 12/244 |
| NauseaGastrointestinal disorders | 14/243 | 12/243 | 14/244 |
| SinusitisInfections and infestations | 13/243 | 14/243 | 9/244 |
| Vulvovaginal mycotic infectionInfections and infestations | 2/243 | 9/243 | 14/244 |
Randomised set (RS): All patients from the screened set (SCR) who were randomised to trial medication regardless of whether any trial medication was taken.
| Age, Continuous(Years) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Mean | 44.2 ± 13.6 | 45.7 ± 12.5 | 45.3 ± 14.0 | 45.0 ± 13.4 |
| Sex: Female, Male(Participants) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Female | 133 | 125 | 131 | 389 |
| Male | 110 | 118 | 113 | 341 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 6 | 17 |
| Not Hispanic or Latino | 236 | 239 | 238 | 713 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching Empagliflozin | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 7 | 6 | 10 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 7 | 6 | 4 | 17 |
| White | 227 | 230 | 230 | 687 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 131 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Apr 2017, 21 months.
Results were first posted in Nov 2018, 1 year 7 months after primary completion. A results delay was requested in Apr 2018.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 21 months is above that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin